The Centre of Membrane Proteins and Receptors (COMPARE), a collaboration between the Universities of Birmingham and Nottingham,has helped produce a video to explain how BMG LABTECH’s PHERAstar and CLARIOstar Microplate Readers are contributing to their work onreceptors involved in cancer progression which are possible anti-cancer therapeutic targets.
The PHERAstar and CLARIOstar Microplate Readers from BMG LABTECH are making vital contributions to the study of a number of diseases, as well as helping to answer fundamental research questions.
Membrane proteins and receptors are critical cellular components and hence implicated in a number of medical conditions as well. At the Centre of Membrane Proteins and Receptors (COMPARE), a collaboration between the Universities of Birmingham and Nottingham, BMG LABTECH's Microplate readers are integral to many of their avenues of research, particular those investigating receptors involved in cancer progression.
CLARIOstar has enabled them to use multiplex assays, permitting important investigations of how receptors can interact with more than one protein simultaneously. Whereas the PHERAstar, in conjunction with CRISPR/Cas9 gene editing, is helping scientists at COMPARE to look at receptor function in both normal physiological and pathophysiological environments. As well as increasing our knowledge of the receptors involved in cancer progression this research also helps indicate possible anti-cancer therapeutic targets.
To learn more about these exciting research strands, and how the PHERAstar and CLARIOstar Microplate Readers from BMG LABTECH are contributing to the investigations at COMPARE, you can now access a video below that features the scientists carrying out this groundbreaking work.
To visit the BMG LABTECH website please click here.
